"Through the above introduction, we can see that the Lerosol" (Fruitflow) "tablets we are going to market this year inhibit the excessive activation of platelets, thereby preventing deep vein thrombosis and pulmonary embolism, reducing the risk of acute myocardial infarction, and preventing sudden exercise death. . At the same time, it can also reduce the release of inflammatory factors, help relieve exercise fatigue, and help shorten the time of exercise recovery. Our recommended taking time is for the general public, especially those over 35 years old. We recommend daily long-term use, and we recommend taking it 1.5-3 hours before strenuous exercise. Regarding Fruitflow® raw materials and products containing the raw materials, we are carrying out human experiments, animal function experiments, and a series of other related functions mechanism research at the same time. In the future, sports cardiovascular protection products will be launched one after another. I hope to have more exchanges with you in the future, thank you."
Relevant studies then had to be carried out in China for SAMR submissions. "The two completed studies (a human study and an animal study) showed excellent results in use for Fruitflow®, and BY-HEALTH intends to make its first blue cap submission to the SAMR for Fruitflow® in February 2019, with a further blue cap submission envisaged later in 2019, both to include references to the Company’s existing European Food Safety Authority (‘EFSA’) health claim for Fruitflow." https://provexis.org/wp-content/uploads/2018/12/PXS_2018-11_Provexis_plc_30-Sep-18_interims_31-Dec-18.pdf
Once the submissions are made to SAMR there is very little By-Health can do but wait and we know SAMR is not a quick process, although it is getting quicker, and we don't know how many Blue Cap submissions have been made so far for Fruitflow but I am sure it will be worth the wait. :)
"cardiovascular protection products will be launched one after another"
"Discover FreeStream Fruitflow®, a blood thinner much better than aspirin that contributes to anticoagulation and prevents building up blood clots. Anticoagulation therapy in regards of blood clots is important in Coronavirus patients. Low doses of anticoagulation can act as prophylactic to prevent COVID-19 patients to develop blood clots." https://www.immunesupp.com/brain-health/
I see the review paper has now had 151 views 46 downloads, Lets hope Mr Duss is forwarding the link to all DSM's customers and potential customers over the weekend. I see the PXS news section has been updated (first time for a while) with the latest papers although it would have been nice to see it in an RNS. https://www.provexis.com/news/
I wonder what part Ruedi Duss had to play in the writing of the review paper? 3.1. Exercise-induced inflammation 3.2. Air pollution 4. Dietary antiplatelets in immunity (to include COVID-19) 5.1. Platelet hyperactivity during menopause 5.2. Erectile dysfunction 5.2. Allergic responses
Whatever DSM's involvement is in the above. 6. Conclusions Platelets have multifaceted functions which give rise to a complicated set of interactions with other vascular cells, leading to many roles outside haemostasis. As our understanding of the role of platelet activation in responding to – and in complicating – inflammatory and infectious illnesses grows, it becomes ever clearer that platelet-targeted treatments are necessary outside the field of CVD. Dietary antiplatelets such as Fruitflow® could help to provide suitably gentle and safe yet efficacious treatments to improve public health in response to a wide range of health challenges.
The Chinese distributor for FF+ is as it will give a better return to Provexis than some other small Chinese product and the By-Health deal is because of the potential quantity of FF they could sell once they have achieved Blue Cap. But make your own mind up.